Mahomedradja, Rashudy F.
van den Beukel, Tessa O.
van den Bos, Maaike
Wang, Steven
Kalverda, Kirsten A.
Lissenberg-Witte, Birgit I.
Kuijvenhoven, Marianne A.
Nossent, Esther J.
Muller, Majon
Sigaloff, Kim C. E.
Tichelaar, Jelle
van Agtmael, Michiel A.
Article History
Received: 19 October 2021
Accepted: 14 February 2022
First Online: 5 March 2022
Declarations
:
: This study and all its methods were performed in accordance with the Declaration of Helsinki. The Medical Ethics Review Board of the Amsterdam UMC – location VUmc approved the study procedures (no. 2021.0090).This study was conducted to evaluate and improve medication safety in a novel patient population of post – COVID-19 patients. Critical assessment of their medication, resulting in detection and reduction of medication-related harm by a multidisciplinary Pharmacotherapy team was the standard of care of the Amsterdam UMC location VUmc’s post - COVID-19 outpatient clinic with no (additional) burden for patients. The results were used to improve medication safety for patients currently recovering or who had recovered from COVID-19 and future patients. Under Dutch law, and approved by the Medical Ethics Review Board of the Amsterdam UMC – location VUmc, it was not required to obtain informed consent from subjects.
: Not applicable.
: The authors declare no conflict of interest.